Antigen receptor gene rearrangements are applied for the PCRbased minimal residual disease (MRD) detection in acute lymphoblastic leukemia (ALL). It is known that ongoing rearrangements result in subclone formation, and that the relapsing subclone(s) can contain antigen receptor rearrangement(s) that differ from the rearrangements found in the major clone(s) at diagnosis. However, the mechanism leading to this so-called clonal evolution is not known, particularly at which time point in the disease the relapsing subclone obtains its (relative) therapy resistance. To obtain insight in clonal evolution, we followed the kinetics of several subclones in three oligoclonal ALL patients during induction therapy. Clone-specific nested PCR for immunoglobulin heavy chain or T cell receptor ␦ gene rearrangements were performed in limiting dilution assays on bone marrow samples taken at diagnosis, at the end of induction therapy and at possible relapse in three children with oligoclonal B-precursor ALL. We demonstrated that in all three patients the subclones were behaving differently in response to therapy. Moreover, in the two patients who relapsed, the clones that grew out during relapse showed the slowest regression or even evoluated during induction therapy and the clones that were not present at relapse showed good response to induction therapy. These results support the hypothesis that at least in some patients already at diagnosis or in the very first weeks, subclones have important differences in respect to resistance. Hence, these data give experimental evidence for the need to develop, during the first months after diagnosis, quantitative PCR assays for at least two different Ig/TCR gene rearrangement targets for every ALL patient. Leukemia (2001) 15, 134-140.
Introduction
The junctional regions of rearranged immunoglobulin heavy chains (IGH) and T cell receptor (TCR) genes can be used as patient-specific PCR targets for the detection of 'minimal residual disease' (MRD) in childhood acute lymphoblastic leukemia (ALL), but the major drawback of these targets is their instability. [1] [2] [3] [4] [5] [6] [7] [8] Therefore, at least two independent monoclonal Ig/TCR targets have to be used for MRD studies to circumvent the loss of hybridization of clonospecific primers or probes. However, false negative results caused by continuing rearrangements have only been described when relapse or impending relapse samples are compared to diagnosis samples. 2, 3, 6 So far, no studies have been performed to investigate whether oligoclonality already hampers the application of antigen receptor PCR-based MRD detection during the initial phases of treatment, whereas the MRD levels at these early time points are used especially for MRD-based risk stratification.
Two hypotheses can be put forward to explain the differential outgrowth of subclones at relapse: (1) the presence of leukemic subclones that already differ in their therapy resistance at diagnosis; (2) the selection of subclones during continuous chemotherapy, possibly by the acquisition of additional genetic event(s) after diagnosis. In the latter situation it should be possible to obtain a reliable estimation of MRD levels at the end of induction therapy by testing only a single PCR target. There are several arguments supporting this second hypothesis, particularly the fact that there is no direct link between antigen receptor rearrangements and the oncogenic process in acute leukemias. A leukemia can be considered as monoclonal with regard to the major oncogenic events. Therefore, it might be possible that during the initial treatment phases leukemias are monoclonal with regard to their response to therapy. In other words, in a relatively therapy-resistant leukemia, all leukemic cells will respond slowly to induction therapy, independently of the antigen receptor rearrangements present in the cells. Although the presence of distinct subclones at diagnosis suggests different biological behavior of these subclones, this is not necessarily so. We have previously shown that the vast majority (80-85%) of childhood ALL patients showed oligoclonality for IGH and TCRD rearrangements at diagnosis, 5, 7 but that this oligoclonality became only visible on Southern blot analysis in patients with a smaller fraction of cells in S-phase. 7 The differential outgrowth of subclones at relapse might then be explained by mutations acquired later in the disease or it might be the result of extreme cell reduction. Indeed, we have previously shown that when leukemic cells obtained at diagnosis from patients with oligoclonal B-precursor ALL are injected into several SCID mice, different subclones can grow out in different mice. 9 To obtain more insight into the mechanisms of clonal evolution, we monitored the kinetics of different subclones in oligoclonal ALL patients during induction therapy.
Materials and methods

Patients and cell samples
The bone marrow samples from children with B-precursor ALL treated in the Emma Kinderziekenhuis/AMC were obtained at diagnosis, at the end of induction therapy and at eventual relapse. All patients were treated according to the BFM strategy-based protocol ALL-VIII of the Dutch Childhood Leukemia Study Group (DCLSG). 10 Induction therapy (28 days) included prednisolone, vincristine, daunorubicin and asparaginase. Additionally methotrexate, prednisolone and cytarabine were administered intrathecally (triple therapy). Total duration of treatment was 2 years. Immunophenotypic and cytogenetic analysis was routinely performed at diagnosis or relapse (Table 1) . DNA was extracted from cryopreserved mononuclear cell fractions, isolated by Ficoll-Hypaque density gradient centrifugation, by means of the QIAamp Blood Kit (Qiagen, Dusseldorf, Germany) as described previously. 11 For Southern blot analysis DNA was digested with BglIl (Life Technologies BRL, Gaithersburg, MD, USA) and hybridized with the H24 JH probe 12 and a J␦1 probe. 13 Three patients were selected on the basis of oligoclonality as assessed by Southern blot analysis (the number of bands exceeded the number of chromosome 14 copies per cell or clear differences were found in the intensity of the bands, indicative of the existence of subpopulations). A single monoclonal patient was studied as a control case.
Target identification
Complete IGH rearrangements were amplified with V H -family-specific framework region one (FR1) primers (V H 1-V H 6) as described by Deane and Norton 14 with a consensus J H -primer (JH21) 15 V␦2D␦3-and D␦2D␦3-rearrangements were amplified with primers V␦2-3/D␦2-3 and D␦3-3 respectively. 15 PCR bands on ethidium-bromide-stained polyacrylamide gels were excised and eluted in water. After a second round PCR with the same primer combination, the PCR product was used as a template in the sequencing reaction using the BRL Cycle Sequencing kit (BRL), with one of the PCR primers endlabelled with 32 P-gamma dATP (Amersham, Buckingham, UK). The products were always sequenced on both strands to eliminate sequencing artefacts. The number of different rearrangements was checked by fingerprinting PCR. This is an analysis of first-round PCR products with 32 P end-labelled consensus JH21 primer (Amersham). By comparing the sequences obtained from different rearrangements it was possible to determine the ongoing rearrangement mechanisms responsible for the oligoclonality in each patient.
Quantification of MRD levels by limiting dilution
To quantify residual leukemic cells, limiting dilution assays were performed with a heminested-patient-specific PCR using a consensus primer set FR3/JH21 or a consensus primer set V␦2-3 or D␦2-3/D␦3-3 in the first reaction and a clone-specific sense primer in the second round on two-fold serialdiluted DNA samples. Reactions were performed in mixtures as previously described. 15 The input of genomic DNA was 1 g per reaction. The PCR protocol took place in a thermal 16 The ratio of leukemic cells to total bone marrow cells was calculated from the ratio of leukemic to Fc-receptor (FCR) targets, considering the presence of one rearranged IGH allele and two FCR genes per cell. Because both nested PCRs are able to detect a single cell, the number of positive PCR reactions at a certain dilution is distributed according to a Poisson distribution, and as such quantification of malignant cells is possible. 17, 18 The mean number of targets required to give a positive reaction was determined by the Taswell method. 19 A computer program, developed at the University of Tilburg and Maastricht by Leo Strijbosch, 20, 21 was used to perform the necessary calculations. 
Leukemia
Single cell PCR
A single cell was sorted on the basis of forward and side scatter properties directly into 50 l PCR tubes using a FACStar (Becton Dickinson Immunocytometric Systems, San Jose, CA, USA). The tubes were spun at 13 000 g for 5 min. Ten l 1 × PCR buffer (Promega) containing 0.25 mg/ml proteinase K was added, and the mixture was covered with mineral oil. Proteinase K digestion took place at 55°C for 1 h and was followed by inactivation at 95°C for 10 min. Subsequently, 40 l of PCR mixture was added to each tube. Amplification consisted of three rounds of PCR. First PCR and nested second round were performed exactly as described previously, 9, 22 with primer pairs V H 3/3′J H 1,2,4,5 and V H 3/5′ J H 1,2,4,5 in the first and the second round, respectively. The third heminested PCR round of 30 cycles was performed with a combination of an ASO primer and a consensus JH21 primer. One l of round-two PCR product was used as a template. For analysis, the third-round product was size-separated by electrophoresis on 10% acrylamide gel. Identity of rearrangements was checked by fingerprinting of the PCR product. The germline IGH rearrangement was identified by a nested PCR approach with primers located precisely before and after the DHQ52-J H 1 junction. In the first round PCR, primer set 5′TATTGGCA-CAAGACTCCAGAGTG3Ј and 5′CCGCTATCCCCAGTA-CAGCAG3Ј was used, whereas in the second round primer set 5′TGGCTGAGCTGAGAACCACTG3Ј and 5′CCACGGT GAGTCAGCCCTGAG3Ј was used.
Results
Case I
Patient I presented with a common ALL at the age of 14 months and experienced a relapse 11 months after initiation of therapy. Southern blot analysis with a H24 JH probe showed three rearrangements in BglII digests at diagnosis. These three rearrangements had different intensities: one major and two minor rearrangements. At relapse the major IGH rearrangement was still present as a major band ( Table 2 ). The minor rearrangements were not detected anymore, and a new rearrangement with the same intensity as the major rearrangement was now seen. With the J␦1 probe only a germline configuration was found at diagnosis and at relapse.
PCR at diagnosis and at relapse:
In this patient five different V H -D-J H joinings were detected by PCR analysis at diagnosis. At relapse only two rearrangements, I-C and I-A2, were detected. Rearrangement I-A2 seemed to be a major clone at relapse by FR3-PCR, while this clone was initially not identified on diagnosis material. The other rearrangements present at diagnosis, I-A1, B and D, were not detectable in the relapse sample (Table 2 ). Sequence analysis revealed that rearrangements I-A1 and I-A2 had identical DLR4-J H 2 joinings and were the result of V H replacements. Rearrangements I-B, C and D were unrelated to these rearrangements (Table 3) . Single cell analysis was performed to investigate which of these sequences represented the two alleles of a cell. Bone marrow cells obtained at diagnosis were sorted to obtain one cell per tube, and V H -D-J H rearrangements were amplified. A total of 67 tubes with FACS-sorted single cells from the sample at diagnosis were analyzed. At least one positive result in one of the junctional region PCRs was obtained in 66 tubes. In 58 I-A2
a H24 JH and J␦1 probes were hybridized to BglII digested DNA. R, relatively major clone; r, relatively minor clone; G, germline. b PCR analysis was performed on undiluted DNA with consensus primers for IGH rearrangements (FR1 and FR3 in combination with JH21) and with consensus primers for TCR␦ rearrangements (V␦2-3 and D␦2-3 in combination with D␦3). 
Quantification of subclones (Table 4):
These results indicated that I-C was the major clonal rearrangement at diagnosis, present in about 79% of the cells. This result was in agreement with the results of the single cell analysis, which indicated that this rearrangement was present as a stable rearrangement in probably all leukemic cells. At diagnosis, this rearrangement was present in the majority of leukemic cells in combination with rearrangement I-A1 or I-B and in only small numbers of cells in combination with rearrangements I-A2 and I-D (3.9% and 1.4% of the mononuclear cells in the bone marrow, respectively). At the end of induction therapy the level of MRD, as measured by the quantification of the stable rearrangement I-C, was about 1.3%. The relative reduction of the different rearrangements varied greatly. In contrast to the diagnosis sample, in which they were presenting as a minor clone, the leukemic cells carrying rearrangement I-C combined with I-A2 were found to be a relatively major clone at the end of induction therapy, with a concentration of 1.6%. Also in the relapse sample, almost all 137  Table 3 Sequence analysis of the various subclones leukemic cells belonged to the clone carrying I-C and I-A2, whereas rearrangements I-A1, I-D and I-B were not or hardly detectable.
Patient Rearrangement Sequence
I I-A1 V H 4 (0) CATCGGACCGGAC GCGTCCCCCT (0) DLR4 (−5) - (−2) J H 2 I-A2 V H 4 (−6) GCGTCCCCCT (0) DLR4 (−5) - (−2) J H 2 I-B V H 4 (−7) TACGGGGGGG (−7) J H 6c I-C V H 3 (0) GGGTCCCGGG (−8) DLR1 (−14) TAGT (0) J H 4a I-D V H 5 (0) CAACCCATAGGG (0) J H 3b II II-A V H 3 (−1) GTCCCCTGT (−4) DLR2 (−1) TTTCTTCAAGGC (0) J H 1 II-B1 V H 3 (0) GATTGGCTGAGTG GAGCCCCGAGCCCTGGGCC (−2) J H 3b II-B2 V H 3 (0) GATGGCGCTCGA GAGCCCCGAGCCCTGGGCC (−2) J H 3b II-B3 V H GATCTGGAGG GAGCCCCGAGCCCTGGGCC (−2) J H 3b II-B4 V H 4 (−1) CGCCAGCTTAG CGAGCCCTGGGCC (−2) J H 3b III III-A1 V H (−6) TTTCATT (−2) J H 5b III-A2 V H (−7) ACTCT (−2) J H 5b III-B V H (−4) TCT (−1) J H 6b III-C1 V H (0) GATAGGGGGCCCAAATACCCGCGGC (−10) Dxp3 (−4) GAGGGGT (0) J H 4b III-C2 V H (0) GATGTGCCTGGGGGGCTTAGGAGATAGGGGGCCCAAATACCCGCGGC (−10) Dxp3 (−4) GAGGGGT (0) J H 4b III-D1 V H (−2) CACAA ATGTG (−13) Dxp2 (−17) GGAGG (−6) J H 6b III-D2 V H (0) G ATGTG (−13) Dxp2 (−17) GGAGG (−6) J H 6b IV IV-A V H 3 (0) TGGGGA (−16) DLR2 TC (−2) J H 6b IV-B V H 3 (−7) TACCTAAGGG (−2) DN4 (0) GG (5) J H 5b IV-VD V␦2 (0) CCCTAGA (−5) D␦3 IV-DD D␦2 (−3
Case II
Patient II was diagnosed with common ALL at the age of 2.5 years, and after a follow-up period of 70 months he is still in continuous complete remission. Southern analysis with the H24 JH probe on the sample taken at diagnosis revealed four rearrangements of equal intensity in BglII digests (Table 2) . Table 2 ). Sequence analysis showed that rearrangement II-A was the only rearrangement with a DLR2 region and J H 1 region. Rearrangements II-B1, II-B2, II-B3 and II-B4 were related, as they shared identical J H 3 regions and no identifiable D region. All rearrangements were supposed to be derived from V H replacements (Table 3) .
PCR analysis at diagnosis: V H -family-specific-FR1 PCR and consensus FR3 PCR analysis revealed five rearrangements (II-A, II-B1, II-B2, II-B3 and II-B4) (
Quantification of subclones (Table 4):
Rearrangement II-A was shown to be the major rearrangement at diagnosis, present in 98% of the cells. Rearrangement II-B1 and II-B4 were also present in relatively large clones. The other rearrangements II-B2 and II-B3 appeared at diagnosis in lower percentages. These percentages were in agreement with the assumption, based on sequence analysis, that rearrangement II-A is present in all cells in combination with one of the other related rearrangements II-B. Also in this patient, the rearrangements had reduced to a different extent at the end of induction. The stable rearrangement showed a large reduction (of Leukemia about 260-fold) comparable to rearrangements II-B1, II-B3 and II-B4 whereas rearrangement II-B2 was not detectable at the end of induction (reduction Ͼ13 000-fold).
Case III
Patient III was diagnosed with common ALL at the age of 5.4 years; he relapsed 19 months after diagnosis. Southern analysis with the H24 JH probe at diagnosis revealed two major rearrangements (R (Table 2) .
PCR analysis at diagnosis and at relapse:
At diagnosis five clonal V H -D-J H rearrangements were found (III-A1, III-A2, III-B, III-C1 and III-D1). At relapse, two new clonal rearrangements, III-C2 and III-D2, were detected and rearrangements III-A1 and III-B, present at diagnosis, were not detectable anymore during relapse (Table 2 ). Sequence analysis revealed V H 3-J H 5b joinings and no D-region in both rearrangements III-A1 and III-A2. Because the junctional region was related (based on deletion of the same two nucleotides at 5′ J H 5b and one identical N-nucleotide) we assume that the rearrangements were a result of V H replacement. Rearrangement III-C1, present at diagnosis and III-C2, only present at relapse had identical DXP3-J H 4b joining and seem to be derived from V H replacements (Table 3) .
Quantification of subclones:
Due to the large number of subclones in patient III, only five rearrangements (III-A1, C1, C2, D1 and D2) were selected for quantification. Again great variation in response to therapy was observed (Table 4) . Two-fold dilutions of DNA were used as input in heminested PCRs using ASO-primers. All reactions were performed in 20 replicas. Using Poisson statistics the relative frequency of the different rearrangements was calculated. The number of cells used as input, was estimated by performing a similar limiting dilution analysis of all DNA samples using a control PCR reaction amplifying a genomic sequence present in each cell. 1 g of DNA as estimated from the A260 extinction was found to be derived from 160 000 to 22 400 cells, indicating that not all DNA samples are equally well amplifiable in the PCR reactions. 95% confidence intervals were determined by the Taswell method.
19-21
The reduction factor, which means the fold reduction achieved during induction therapy, was calculated by dividing the relative frequency at diagnosis by the relative frequency at the end of induction therapy.
Rearrangement III-A1 showed the highest incidence at diagnosis, but decreased very rapidly in response to therapy and was not detectable anymore in the relapse sample. Rearrangement III-C1 and III-D1 were present in major clones at diagnosis and were reduced at the end of induction therapy to similar levels (0.3-0.5%). Surprisingly, the rearrangements III-C2 and III-D2, which both could not be detected at diagnosis, were present at the end of induction therapy, III-D2 even at a relatively high level (2.3%). Both rearrangements (III-C2 and III-D2) were also present in the leukemic cells at relapse, accompanied by III-C1 and III-D1.
Case IV
Patient IV was diagnosed with common ALL at the age of 3.3 years and relapsed 6 months after initiation of therapy. Despite a trisomy 14, on Southern blot analysis with the H24 JH probe only two major bands of equal intensity were seen in BglII digests. Thus most likely the duplication of chromosome 14 has occurred after IGH rearrangement (Table 2) .
PCR analysis at diagnosis and at relapse:
Both V H 3-FR1 PCR and consensus FR3 PCR amplification of the V H -D-J H rearrangements revealed two rearrangements, IV-A and IV-B, in diagnosis and relapse samples. Neither rearrangements were related to each other. By applying V␦2D␦3 and D␦2D␦3 primers, two rearrangements were detected at the TCRD level: one V␦2D␦3 rearrangement (IV-VD) and one D␦2D␦3 rearrangement (IV-DD) ( Table 2) . Amplification of the leukemic rearrangements in the bone marrow sample obtained at relapse resulted in the same four rearrangements.
Single cell analysis:
Single cell analysis of V H -D-J H rearrangements at diagnosis was performed. At the same time, V␦2D␦3 and D␦2D␦3 rearrangements of the TCRD gene were also amplified by three rounds of heminested PCR. Rearrangements IV-A, IV-B, IV-VD and IV-DD were co-amplified in 50 of the 150 tubes tested. From these results we conclude that probably all rearrangements occur in the same cell, confirming the monoclonal status of this patient.
Quantification of subclones:
Statistical analysis of patient IV showed the presence of IGH rearrangements IV-A and IV-B in comparable ratios of 116% and 130%, respectively, TCRD rearrangements, IV-VD and IV-DD, appeared in higher concentration in comparison to the IGH rearrangements (260%). At the end of induction therapy, the average reduction was for all rearrangements in the same range (200-500). At relapse, all rearrangements were detected in similar amounts.
Discussion
The general assumption for MRD detection based on antigen receptor targets is that at least two independent IGH/TCR PCR targets have to be used to minimize the risk of false negativity due to clonal diversity. [1] [2] [3] [4] [5] [6] [7] [8] However, so far no data are available as to whether oligoclonality is already hampering MRD detection during the early treatment phases. In the present study we demonstrated that the various subclones at diagnosis in three patients strongly differ in their response to induction therapy.
By determining precisely the concentration of the various oligoclonal IGH gene rearrangements at diagnosis and at the end of induction therapy, we were able to calculate the reduction factor of each IGH rearrangement in response to induction therapy. Since cellularity of the bone marrow is higher at diagnosis than at the end of induction therapy, the reduction rates should be considered as relative values. The equal reduction of all IGH rearrangements in the patient without detectable subclones (patient IV) supports the reliability of these kinetic studies. By detailed analysis of the DNA sequences of the junctional regions and in some cases by single cell PCR, we were able to identify which IGH gene rearrangements were present in the different subclones of the patients. In this way we demonstrated that the various subclones showed strongly different reduction rates, varying from two-fold to more then 13 000-fold. Furthermore, it was shown that the rearrangements present in the relapsing subclones (I-A2, I-C, III-C1, III-C2 and III-D) showed the slowest reduction during induction therapy, whereas the rearrangements that were reduced quickly in response to therapy (I-A1, I-D and III-A1) were not detectable at relapse. These data demonstrate that (at least in oligoclonal ALL) the relapse-causing subclones already show a different biological behavior at the very beginning of the disease and are not selected during therapy by ongoing genetic events under chemotherapeutic pressure. In this respect it is interesting that in one of the relapsing patients (patient III) two rearrangements (III-C2 and III-D2), present in the relapse sample were not detectable in the diagnosis sample but were detected at the end of induction therapy. Presumably, these rearrangements were present in small leukemic subclones at diagnosis which were below the detection limit. Apparently these subclones were hardly responsive to induction therapy and were therefore selected during therapy. Our analyzed data suggest that the increased risk of relapse in patients with slow regression of MRD during induction therapy 6, [23] [24] [25] [26] [27] [28] [29] [30] is caused by therapy-resistant leukemic cells already present at diagnosis. This notion is more likely than the idea that in these patients, just by the longer persistence of (only relatively therapy-resistant) leukemic cells, an increased risk exists that with time some leukemic cells become therapyresistant by the acquisition of additional mutations. However, before this conclusion can be drawn, more patients have to be studied. Three extremely oligoclonal patients (all had at least five different IGH rearrangements) were investigated and two patients relapsed during therapy. It has to be studied whether in all oligoclonal patients and also in patients that relapse off-therapy, the various subclones behave differently. We show in the present study that in the absence of a real genetic marker for therapy resistance, antigen receptor rearrangements may serve as surrogate markers that allow the tracking of cell populations with differential response to therapy.
Our results have direct consequences for the strategy of MRD detection. We show for the first time that during induction therapy oligoclonality may already hamper the antigen receptor-based PCR approach. It further stresses the importance to screen for oligoclonality at diagnosis and to select for stable monoclonal PCR targets. However, this will not always be possible. If only oligoclonal targets are available, PCRs have to be developed that enable the detection of the different subclones. In contrast to the approach in the present study one does not have to select for clonospecific primers or probes that detect the subclones separately, but preferentially primers or probes have to be designed that detect all subclones of a patient simultaneously. As previously described, this might be achieved in most cases with oligoclonal IGH Leukemia gene rearrangements by designing D-N-J H primers or probes. 2, 7, 31 The findings presented in this paper may also be relevant for monoclonal patients. Also in these apparently monoclonal patients subclones that are less responsive to therapy may be present at diagnosis, and it might be possible that in these resistant subclones ongoing IGH and/or TCR rearrangements have already taken place. In view of our present results and also of the growing evidence that oligoclonal leukemias behave more aggressively, 32 it is tempting to speculate that the factors that promote clonal diversity are also involved in inducing a more aggressive phenotype. Such a factor might be an active recombinase machinery that might also lead to instability elsewhere in the genome. In that case a small therapy-resistant subclone present at diagnosis or selected during the first weeks of treatment might not be detected by the clonospecific primers/probes at the end of induction therapy. Therefore, in monoclonal patients different PCR targets also have to be applied to minimize the risk that these small subclones are missed during PCR follow-up.
In conclusion, we have shown that in oligoclonal patients leukemic subclones can occur that differ in their response to induction therapy. Our results demonstrate that quantification of MRD can be used to better understand clonal evolution of leukemia during treatment. Our findings suggest that in some patients therapy-resistant subclones emerge very early during treatment. Given the poor results of patients with relapsed leukemia, this might indicate that patients with high levels of MRD at the end of induction therapy may already suffer at that moment from therapy-resistant leukemia and may not be cured with current chemotherapy. Furthermore, our results have direct impact for the optimal strategy for monitoring of MRD in early treatment phases: at the first sampling time points at least two different antigen receptor PCR targets have to be studied. This means that in a very short time span after diagnosis of B-precursor ALL, it has to be investigated which antigen-receptor targets are oligoclonal, and quantitative PCRs 33 have to be developed for at least two different Ig/TCR gene rearrangement targets.
